real-time news and commentary for investors
Tuesday, Sep 3
BMY, Pfizer's Eliquis better than Warfarin in sub-group
- Bristol-Myers Squibb (BMY) and Pfizer (PFE) say a trial sub-analysis of their Eliquis blood-thinner compared with the generic warfarin in 4,808 patients with or without some types of valvular heart disease was consistent with the overall results of the study, known as Aristotle.
- In the subanalysis, which accounted for over a quarter of the patients in the testing, Eliquis reduced stroke or systemic embolism, caused fewer major bleeding events, and reduced all-cause mortality. (PR)
- Also see: Daiichi Sankyo's edoxaban meets primary endpoint.